Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis

被引：0
|
作者：
Knowles, Susan [1 ]
Taroumian, Sara [1 ]
Lisse, Jeffrey R. [1 ]
Yanes, James [1 ]
Ampel, Neil M. [2 ]
Gall, Eric P. [3 ]
Grau, Rafael G. [1 ]
Bode, Barbara Y. [2 ]
Vaz, Berchman A. [4 ]
Galgiani, John [5 ]
Hoover, Susan E. [1 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] So AZ VA Med Ctr, Tucson, AZ USA
[3] Arizona Arthrit Ctr, Tucson, AZ USA
[4] Catalina Pointe Arthrit & Rheumatol, Tucson, AZ USA
[5] Valley Fever Ctr Excellence, Tucson, AZ USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2466
引用
收藏
页码：S961 / S961
页数：1
相关论文
共 50 条
  • [41] The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
    Goralczyk, Alicja
    Kolossa, Katarzyna
    Waszczak-Jeka, Marzena
    Adamczak, Rafal
    Jeka, Slawomir
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 306 - 312
  • [42] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [43] PROTOCOL DEVELOPMENT FOR COMBINATION THERAPY WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    PAULUS, HE
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (02) : 19 - 25
  • [44] AN UPDATED MIXED TREATMENT COMPARISON OF BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Rodriguez, M. F.
    Balmaceda, C.
    Espinoza, M. A.
    Rojas, R.
    Vargas, C.
    Dominguez, A.
    Duran, J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S95 - S96
  • [45] Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
    Bergman, Gert J. D.
    Hochberg, Marc C.
    Boers, Maarten
    Wintfeld, Neil
    Kielhorn, Adrian
    Jansen, Jeroen P.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (06) : 425 - 441
  • [46] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano
    Behlouli, Hassan
    Curtis, Jeffrey
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 937 - 938
  • [47] COMPARATIVE EFFECTIVENESS OF TOFACITINIB, BIOLOGIC DRUGS AND TRADITIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Moura, C. S.
    Machado, M. A.
    Behlouli, H.
    Curtis, J. R.
    Abrahamowicz, M.
    Bernatsky, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 825 - 826
  • [48] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano S.
    Behlouli, Hassan
    Curtis, Jeffiey R.
    Bernatsky, Sasha
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [49] Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis
    Marguerie, L
    Flipo, RM
    Grardel, B
    Beaurain, D
    Duquesnoy, B
    Delcambre, B
    JOINT BONE SPINE, 2002, 69 (03) : 275 - 281
  • [50] METHOTREXATE USE AND THE RISK FOR CARDIOVASCULAR DISEASE AMONG RHEUMATOID PATIENTS INITIATING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Xie, F.
    Chen, L.
    Yun, H.
    Levitan, E.
    Muntner, P.
    Curtis, J. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 145 - 145
12345